Alternatives to Sightera Biosciences
Sightera Biosciences is a Biotechnology tool: aI drug discovery startup that learns directly from patient biology to identify and design novel medicines, focusing on oncology and fibrosis. Here are the 60 closest alternatives, compared on pricing, features and what real users say.
Sightera Biosciences profileOpen source alternatives (15)More Biotechnology alternatives
The 20 closest Biotechnology companies to Sightera Biosciences
- Website
Isomorphic Labs68Drug DiscoveryLondon, United Kingdom$4.7BAI-driven drug discovery spinoff from DeepMind using AlphaFold to discover novel medicines.
- Website
Graph Therapeutics44BiotechnologyBoston, Austria$5.0MDeveloping precision medicines for inflammatory and immune-mediated diseases using AI and patient sample analysis.
- Website
Chai Discovery59Artificial IntelligenceSan Francisco, United States$871.5MAI-powered drug discovery platform using foundation models for molecular design.
- Website
Insilico Medicine24BiotechHong Kong, ChinaA clinical-stage AI drug discovery company accelerating the development of novel therapeutics for various diseases.
- EXExscientia2HealthcareOxford, United Kingdom
- Website
Infinimmune60BiotechnologyAlameda, United States$75.0MDeveloping human-derived antibodies for inflammatory diseases and cancer using AI and proprietary platforms.
- EAEarendil Labs56BiotechnologyBeijing, China$787.0M
Earendil Labs is an AI biotechnology company focused on leveraging artificial intelligence for drug discovery and development of next-generation biologics.
- Website
Sinopia Biosciences54BiotechnologySan Diego, USA$2.2MBiotechnology company advancing novel therapeutics using its proprietary LEADS drug discovery platform.
- Website
Moderna77BiotechnologyCambridge, United States$4.5BModerna is a biotechnology company pioneering mRNA medicine, best known for its COVID-19 vaccine and a broad pipeline of mRNA-based therapeutics.
- Website
BioNTech66BiotechnologyMainz, Germany$975.0MGlobal biopharmaceutical company pioneering mRNA-based immunotherapies and vaccines for cancer and infectious diseases.
- Website
Pixelgen Technologies62BiotechnologyStockholm, Sweden$43.5MA life sciences company that has developed a high-throughput platform for mapping molecular cell architecture at nanoscale resolution.
- Website
Degron Therapeutics62BiotechnologySan Diego, USA$40.0MClinical-stage biotechnology company advancing molecular glue degrader (MGD) medicines.
- Website
Network Bio60BiotechnologyPalo Alto, United States$100.0MLeveraging AI and a massive patient tissue dataset to accelerate drug discovery and advance precision medicine.
- Website
LifeMine Therapeutics Inc.60BiotechnologyWatertown, United States$543.0MClinical-stage biopharmaceutical company leveraging a proprietary platform to discover and develop novel precision medicines from fungi.
- Website
Adcendo60BiotechnologyCopenhagen, Denmark$272.0MDeveloping first-and best-in-class antibody-drug conjugates (ADCs) for cancers with high unmet medical need.
- Website
CellCentric60BiotechnologyCambridge, United Kingdom$375.0MA clinical-stage biotechnology company developing inobrodib as a first-in-class, oral p300/CBP inhibitor for the treatment of multiple myeloma.
- Website
Enterome60BiotechnologyParis, France$123.9MClinical-stage biopharmaceutical company developing microbiome-derived immunotherapies for cancer and immune diseases.
- Website
4D Path59BiotechnologyNewton, USA$17.4MPersonalizing cancer care through a novel, physics-informed approach to predict tumor response to therapy.
- Website
Janux Therapeutics57BiotechnologySan Diego, USA$181.0MA clinical-stage biopharmaceutical company developing novel immunotherapies.
- Website
KaliVir Immunotherapeutics, Inc.57BiotechnologyPittsburgh, United States$14.0MClinical-stage biotechnology company developing multi-mechanistic oncolytic immunotherapy programs for cancer treatment.
Showing the 20 closest matches. See the rest on the Sightera Biosciences profile.
Compare Sightera Biosciences head to head
Side by side on what each one does, what it costs, and what real users report.